Clinical Trials in Ohio

Showing 5401-5420 of 20,938 trials

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab may enhance the effectiveness of a standard chemotherapy (DA-EPOCH) in patients with plasmablastic lymphoma.

Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more

AIDS Malignancy Consortium15 participantsStarted May 2021

Miami, Florida, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +5 more locations

RECRUITING32 miles

Early Predictors of Necrotizing Enterocolitis in Neonates

NCT03210831

The goal of this project is to identify neonates who are predisposed to Necrotizing Enterocolitis (NEC). the investigators will determine the effectiveness of non-invasive measures as well as biochemical markers to identify neonates early in the disease process. Thus, the investigators aim to identify infants with NEC prior to the onset of symptoms to institute or test treatments in the long term to prevent the progression of the disease in these infants.

Necrotizing Enterocolitis

Nationwide Children's Hospital450 participantsStarted Sep 2017

Columbus, Ohio, United States

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Early Predictors of Necrotizing Enterocolitis in Neonates

Find Trials by Condition in Ohio

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Distal Radius Interventions for Fracture Treatment

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

A Study to Investigate LYL797 in Adults With Solid Tumors

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial)

Beacon Sensors and Telerehabilitation for Low Vision

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Gluten Technology and Education for Celiac Health

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cough Reduction in IPF With Nalbuphine ER

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates